未登录

G

Gabriella Campadelli-Fiume

university of bologna

H指数:54

被引数:9,405

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers (vol 10, 1149973, 2023)

FRONTIERS IN MOLECULAR BIOSCIENCES

IF4

2024-06-250

OAAI

Oncolytic virotherapy induces a long-term immune antitumoral response leading to glioma eradication

CANCER RESEARCH

IF16.6

2024-03-220

PRE

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers

FRONTIERS IN MOLECULAR BIOSCIENCES

IF4

2023-05-115

OAAI

Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV

IF3.5

2021-10-163

OAAI

Genotype of Immunologically Hot or Cold Tumors Determines the Antitumor Immune Response and Efficacy by Fully Virulent Retargeted oHSV

IF3.5

2021-09-017

OAAI

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma

IF3.5

2021-08-249

OAAI

Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment

MOLECULAR THERAPY-ONCOLYTICS

IF0

2020-12-0125

OAAI

y Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis

SCIENTIFIC REPORTS

IF3.9

2020-03-0922

OAAI

αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion

Αvβ3-整合素调节PD-L1表达并参与癌症免疫逃避

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2019-09-1658

OAAI

Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model

IF7.3

2019-02-1261

OAAI

A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors

IF4.9

2018-08-0667

OAAI

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses

IF3.5

2018-06-3039

OAAI

Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells

JOURNAL OF VIROLOGY

IF3.8

2018-03-1515

OAAI

Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors

JOURNAL OF VIROLOGY

IF3.8

2018-03-157

OAAI

A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells

JOURNAL OF VIROLOGY

IF3.8

2017-05-1523

OAAI

Insertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins

IF4.9

2017-04-1933

OAAI

αvβ3 Integrin Boosts the Innate Immune Response Elicited in Epithelial Cells through Plasma Membrane and Endosomal Toll-Like Receptors

JOURNAL OF VIROLOGY

IF3.8

2016-04-1515

OAAI

Retargeting Strategies for Oncolytic Herpes Simplex Viruses

IF3.5

2016-02-2644

OAAI

Dissociation of HSV gL from gH by αvβ6-or αvβ8-integrin promotes gH activation and virus entry

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2015-07-0852

OAAI

The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors

IF4.9

2015-05-2135

OAAI